Interventions to improve return to work in depressed people.

Background: Work disability such as sickness absence is common in people with depression.

Objectives: To evaluate the effectiveness of interventions aimed at reducing work disability in employees with depressive disorders.

Search Methods: We searched CENTRAL (The Cochrane Library), MEDLINE, Embase, CINAHL, and PsycINFO until April 4th 2020.

Interventions to improve return to work in depressed people.

Background: Work disability such as sickness absence is common in people with depression.

Objectives: To evaluate the effectiveness of interventions aimed at reducing work disability in employees with depressive disorders.

Search Methods: We searched CENTRAL (The Cochrane Library), MEDLINE, EMBASE, CINAHL, and PsycINFO until January 2014.

Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.

Objective: To describe the effect of indirect costs for patients with early rheumatoid arthritis (RA) within the COBRA trial (Combinatietherapie Bij Reumatoide Artritis) on the cost-effectiveness of both therapies. Analyses of the efficacy and direct costs of the treatments have already been reported.

Methods: Patients with early RA selected for the 56-week trial were randomly assigned to prednisolone, methotrexate, and sulfasalazine (the COBRA combination) (n = 76, tapered after 28 weeks) or to sulfasalazine (SSZ; n = 79, of which 78 patients were evaluable) alone.

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.

Objective: The Combinatietherapie Bij Reumatoide Artritis (COBRA) trial demonstrated that step-down combination therapy with prednisolone, methotrexate, and sulfasalazine (SSZ) was superior to SSZ monotherapy for suppressing disease activity and radiologic progression of rheumatoid arthritis (RA). The current study was conducted to investigate whether the benefits of COBRA therapy were sustained over time, and to determine which baseline factors could predict outcome.

Methods: All patients had participated in the 56-week COBRA trial.